This IP is a cutting-edge innovation engineered to combat neuroblastoma, a form of tumor primarily affecting children. This oncolytic virus, developed through an NIH U54 supplemental grant, targets tumor-associated antigens and harnessing the power of the immune system. The IP entails the creation of a sophisticated virus capable of expressing both a neuroblastoma antigen (Phox2B) and interferon gamma (IFN gamma). The Phox2B antigen aids in improving Major Histocompatibility Complex Class I (MHCI) upregulation, thereby enhancing immune recognition of the tumor. Additionally, the expression of IFN gamma further boosts MHCI expression in responsive tumors, augmenting both native T cell activity and engineered CAR-T cell response. One of the key advantages of this technology lies in its early generation ICP34.5 (-) backbone virus, which facilitates easier FDA approval due to prior clinical trial experience in pediatric settings. By leveraging this well-established backbone, the oncolytic virus offers a promising avenue for the treatment of neuroblastoma while minimizing regulatory hurdles. The potential applications of this innovative technology are multifaceted. As a standalone therapy, it is a compelling option for patients with neuroblastoma or tumors expressing the Phox2B antigen. When combined with engineered CAR-T therapy targeting the MHCI-associated antigen, the oncolytic virus holds the potential to synergistically enhance anti-tumor activity. Such combination therapy not only increases antigen density—thus overcoming potential CAR-T evasion mechanisms—but also leverages the early generation backbone for swift translation into clinical use. Further development of the IP involves pre-clinical testing in conjunction with CAR-T therapy. By partnering with collaborators and regulatory authorities, the goal is to advance this technology towards FDA approval and ultimately bring it to patients in need.